Meeting NewsVideo

VIDEO: Tumor size, node status, age affect risk for breast cancer mortality

CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today about a study that assessed contributing factors for breast cancer-specific mortality over a period of 20 years.

The study revealed that larger tumor size, higher node status, older and younger age and higher tumor grade were markedly associated with breast cancer mortality, Leone said.

The risk for breast cancer-specific mortality was five times less likely than the risk for death from other causes in patients with early-stage breast cancer, according to Leone. Conversely, patients with later-stage breast cancer were twice as likely to die from breast cancer than other causes.

These results have the potential to aid in intervention recommendations after breast cancer is diagnosed, he said. – by Alaina Tedesco

 

Reference:

Leone JP, et al. Abstract 540. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Leone reports receiving research funding from Eli Lilly and Company, Kazia Therapeutics, Merck Sharp & Dohme and Seattle Genetics.

CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today about a study that assessed contributing factors for breast cancer-specific mortality over a period of 20 years.

The study revealed that larger tumor size, higher node status, older and younger age and higher tumor grade were markedly associated with breast cancer mortality, Leone said.

The risk for breast cancer-specific mortality was five times less likely than the risk for death from other causes in patients with early-stage breast cancer, according to Leone. Conversely, patients with later-stage breast cancer were twice as likely to die from breast cancer than other causes.

These results have the potential to aid in intervention recommendations after breast cancer is diagnosed, he said. – by Alaina Tedesco

 

Reference:

Leone JP, et al. Abstract 540. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Leone reports receiving research funding from Eli Lilly and Company, Kazia Therapeutics, Merck Sharp & Dohme and Seattle Genetics.

    See more from Discoveries from ASCO: Breast Cancer